- Home
- CANF vs CNFR Comparison
CANF vs CNFR Comparison
Compare CANF & CNFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- CNFR
- Stock Information
- Founded
- CANF 1994
- CNFR 2009
- Country
- CANF Israel
- CNFR United States
- Employees
- CANF N/A
- CNFR N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- CNFR Property-Casualty Insurers
- Sector
- CANF Health Care
- CNFR Finance
- Exchange
- CANF Nasdaq
- CNFR Nasdaq
- Market Cap
- CANF 14.4M
- CNFR 14.2M
- IPO Year
- CANF N/A
- CNFR 2015
- Fundamental
- Price
- CANF $1.48
- CNFR $1.07
- Analyst Decision
- CANF Strong Buy
- CNFR
- Analyst Count
- CANF 2
- CNFR 0
- Target Price
- CANF $14.00
- CNFR N/A
- AVG Volume (30 Days)
- CANF 1.2M
- CNFR 16.2K
- Earning Date
- CANF 12-31-2024
- CNFR 11-13-2024
- Dividend Yield
- CANF N/A
- CNFR N/A
- EPS Growth
- CANF N/A
- CNFR N/A
- EPS
- CANF N/A
- CNFR 2.40
- Revenue
- CANF $667,000.00
- CNFR $74,815,000.00
- Revenue This Year
- CANF $409.56
- CNFR N/A
- Revenue Next Year
- CANF N/A
- CNFR $7.00
- P/E Ratio
- CANF N/A
- CNFR $0.44
- Revenue Growth
- CANF N/A
- CNFR N/A
- 52 Week Low
- CANF $1.29
- CNFR $0.65
- 52 Week High
- CANF $4.69
- CNFR $1.91
- Technical
- Relative Strength Index (RSI)
- CANF 35.58
- CNFR 40.52
- Support Level
- CANF $1.30
- CNFR $1.04
- Resistance Level
- CANF $1.72
- CNFR $1.19
- Average True Range (ATR)
- CANF 0.18
- CNFR 0.07
- MACD
- CANF -0.01
- CNFR -0.01
- Stochastic Oscillator
- CANF 17.92
- CNFR 29.41
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About CNFR Conifer Holdings Inc.
Conifer Holdings Inc is an insurance company engaged in the sale of property and casualty insurance products. It is engaged in three classes of insurance businesses namely commercial lines, personal lines, and wholesale agency business. Within these three businesses, the company offers various insurance products and insurance agency services. The company views the commercial and personal lines segments as underwriting business. The wholesale agency business provides non-risk bearing revenue through commissions and policy fees. Its revenues are derived from premiums earned from insurance operations.